Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imiquimod 5% Cream Cycling for Actinic Keratoses
NCT00175643Phase 3Completed
- Sponsor
- University of British Columbia
- Start
- Feb 2005
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of imiquimod in actinic keratosis (AK), sponsored by University of British Columbia. Primary endpoint: Complete clearance rate. Started Feb 2005; status: completed.
02
Drugs
imiquimod
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT00175643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00175643.